• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

    7/10/24 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email

    SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results.

    During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter.

    Investors and other interested parties may join the live audio webcast of the call via this weblink.

    A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes.

    ABOUT LEGEND BIOTECH

    Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

    Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

    INVESTOR CONTACT:

    Jessie Yeung

    Tel: (732) 956-8271

    [email protected]

    PRESS CONTACT:

    Mary Ann Ondish

    Tel: (914) 552-4625

    [email protected]



    Primary Logo

    Get the next $LEGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    4/17/2024$65.00Sector Perform → Sector Outperform
    Scotiabank
    4/3/2024$82.00Overweight
    Cantor Fitzgerald
    3/13/2024$86.00Outperform
    Raymond James
    12/19/2023Sector Perform
    Scotiabank
    More analyst ratings